GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » Current Ratio

23andMe Holding Co (23andMe Holding Co) Current Ratio : 2.15 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. 23andMe Holding Co's current ratio for the quarter that ended in Dec. 2023 was 2.15.

23andMe Holding Co has a current ratio of 2.15. It generally indicates good short-term financial strength.

The historical rank and industry rank for 23andMe Holding Co's Current Ratio or its related term are showing as below:

ME' s Current Ratio Range Over the Past 10 Years
Min: 2.15   Med: 3.26   Max: 6.77
Current: 2.15

During the past 4 years, 23andMe Holding Co's highest Current Ratio was 6.77. The lowest was 2.15. And the median was 3.26.

ME's Current Ratio is ranked worse than
50.84% of 238 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.23 vs ME: 2.15

23andMe Holding Co Current Ratio Historical Data

The historical data trend for 23andMe Holding Co's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

23andMe Holding Co Current Ratio Chart

23andMe Holding Co Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Current Ratio
- 2.58 3.93 2.84

23andMe Holding Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.54 2.84 3.03 2.93 2.15

Competitive Comparison of 23andMe Holding Co's Current Ratio

For the Diagnostics & Research subindustry, 23andMe Holding Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


23andMe Holding Co's Current Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, 23andMe Holding Co's Current Ratio distribution charts can be found below:

* The bar in red indicates where 23andMe Holding Co's Current Ratio falls into.



23andMe Holding Co Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

23andMe Holding Co's Current Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Current Ratio (A: Mar. 2023 )=Total Current Assets (A: Mar. 2023 )/Total Current Liabilities (A: Mar. 2023 )
=424.992/149.416
=2.84

23andMe Holding Co's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=309.959/144.139
=2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


23andMe Holding Co  (NAS:ME) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


23andMe Holding Co Current Ratio Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


23andMe Holding Co (23andMe Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Executives
Kathy L Hibbs officer: See Remarks C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards officer: Head of Therapeutics Discovery 160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage officer: Interim CFO 490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan officer: Head of Therapeutics C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell director, officer: Chief Financial Officer 27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md director BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson officer: VP, General Manager-Consumer 440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim officer: See Remarks 6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon officer: Vice President, Engineering 1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch officer: See Remarks 2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler officer: Vice President, People 1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p. 10 percent owner 2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc 10 percent owner 171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki director, 10 percent owner, officer: Chief Executive Officer C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606